PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer

Bergqvist P, et al. American Association for Cancer Research® (AACR) Annual Meeting, April 2025, April 2025

This poster describes preclinical data on AbCellera’s PSMA x CD3 T-cell engagers (TCEs) for the treatment of metastatic castration-resistant prostate cancer. TCEs were generated by pairing diverse CD3- and PSMA-binding antibodies and using empirical testing to assess how TCE parameters impact function.

Together, the data presented show:

• Potent in vitro tumor-cell killing, with one molecule showing ~10x lower EC₅₀ than benchmark
• Sustained in vitro activity across four rounds of serial T-cell killing
• Preclinical in vivo efficacy, with significant tumor growth inhibition in a xenograft mouse model
• Potential for enhanced potency when combined with costimulatory PSMA x CD28 bispecifics